Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, promotes weight loss in patients with type 2 diabetes mellitus and obesity. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.